BeOne Medicines stock: first look at recent performance

BeOne Medicines (ONC) has drawn fresh attention after its recent trading session, with the share price closing at $320.37 and short term returns showing mixed moves over the past week, month, and past 3 months.

Despite the 1-day share price return of a 4.04% decline taking the stock to $320.37, the 1-year total shareholder return of 80.10% points to strong longer term momentum that currently appears to be cooling.

If BeOne Medicines has caught your eye, this can be a good moment to compare it with other healthcare names and see what stands out in healthcare stocks.

With BeOne Medicines trading at $320.37, an intrinsic value estimate that implies a 65.55% discount and a 1 year total return of 80.10%, you have to ask yourself: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 20.2% Undervalued

With BeOne Medicines closing at $320.37 against a narrative fair value of about $402, the valuation case leans heavily on its oncology pipeline and earnings potential.

BeOne's rapid commercial expansion into new international markets and increasing product launches (with 87% Europe revenue growth and "Rest of World" up 168%, plus >75 countries approved), combined with product mix improvements and new formulations like BRUKINSA's tablet, provide catalysts for incremental revenue and continued gross margin improvement.

Curious what kind of future revenue, margin lift and earnings multiple are baked into that fair value? The narrative ties all three together in a tight set of assumptions.

The most followed narrative applies a 6.75% discount rate and assumes rising profitability and a higher future earnings multiple to arrive at a fair value of roughly $402 per share. This suggests that BeOne Medicines is trading at a sizeable discount to those projections today.

Result: Fair Value of $402 (UNDERVALUED)

However, this hinges on clinical and regulatory success, and setbacks around BRUKINSA concentration or key trial readouts could quickly weaken the current bullish narrative.

Build Your Own BeOne Medicines Narrative

If you look at these numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a custom view of BeOne in a few minutes with Do it your way.

A great starting point for your BeOne Medicines research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If BeOne Medicines feels interesting but you want a wider watchlist, now is the time to broaden your view and spot opportunities others might overlook.

• Supercharge your hunt for smaller names with big potential by scanning these 3545 penny stocks with strong financials that already show stronger fundamentals than many peers.
• Ride the AI wave with focus by zeroing in on these 28 AI penny stocks that are directly tied to real-world applications and growing demand for intelligent software.
• Target value opportunities upfront by filtering for these 881 undervalued stocks based on cash flows where current prices sit below cash flow based estimates.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.